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lhis has been an exciting meeting with much new infor-
ation presented about myocardial ischemia and infarction.
e covered several areas, including: new treatment modal-
ties and care strategies for patients presenting with ST-
egment elevation myocardial infarction (MI); new treat-
ents for non–ST-segment elevation acute coronary
yndromes (ACS); and acute ischemic heart disease in
omen, a key theme this week for the overall meeting. We
iscussed the growing importance of understanding risk,
ncluding diabetes and inflammation, among ACS patients
nd also addressed some interesting new and relevant
nformation in coronary artery bypass graft surgery. Finally,
e closed with an important message from this meeting—
he application of evidence-based medicine in our practices.
T-segment elevation acute MI. Dr. Stone presented the
nhanced Myocardial Efficacy and Removal by Aspiration
f Liberated Debris (EMERALD) study, a randomized
rial that compared a distal embolization protection device
ersus control in patients undergoing primary angioplasty
1). Overall, this trial showed no benefit of the guide wire
echnology in these patients, despite having met its mech-
nistic goal of capturing embolic material in upwards of 75%
f patients. There are two important lessons here for
hysicians involved in the care of ST-segment elevation MI
atients. First, remember that intuition is not data. Al-
hough it is important to understand the mechanism behind
hy things work, we need to study them in randomized
linical trials to know if the new therapy or technology
ctually provides clinical benefit. Second, we need to think
bout moving beyond the epicardial coronary vessel to
nderstand ways to better protect the myocardium.
A major topic at these meetings has been the notion of
entralization of care and transfer of the acute MI patient.
here has been a great deal of uncertainty about the optimal
trategy for ST-segment elevation MI. Is it fibrinolysis? Is it
rimary angioplasty? Is it some combination of these? What
bout transfer to regional care centers? Important work was
resented from the American College of Cardiology
ACC)-National Cardiovascular Data Registry (NCDR)
atabase regarding patients who were transferred for ST-
egment elevation primary angioplasty (2). Approximately
ne-half of those patients received fibrinolysis before trans-
er, and after adjusting for other variables there was a better
ortality rate among these patients. This opens up the
uestion of what is actually optimal care. It is probably not
ne therapy or the other, but likely involves combinations of
are. And a key question that the ACC and investigators
From the Duke Clinical Research Institute, Duke University Medical Center,
ourham, North Carolina.eed to address is: what are the most appropriate systems for
cute MI care regarding transfer and the centralization or
egionalization of heart attack centers?
Holmes et al. (3) from the Mayo Clinic presented some
mportant information on shock in the ST-segment eleva-
ion population. He provided an 11-year follow-up on the
riginal Global Utilization of Streptokinase and TPA for
ccluded arteries (GUSTO I) shock cohort. Such patients
ccount for approximately two-thirds of the early deaths
ssociated with acute MI. However, for patients who are
ble to survive that early shock period, the rate of death over
he next decade is very similar to that of the non-shock
opulation. This has important ramifications as we think
bout emerging therapies for the care of shock.
on–ST-segment elevation ACS. Much information has
een presented at these meetings regarding antithrombotic
herapy, which remains the cornerstone of therapy for this
roup of patients. Currently, there are oral antiplatelet,
ntravenous antiplatelet, and antithrombin therapies, as well
s emerging therapies that inhibit coagulation more proxi-
ally rather than downstream in the coagulation cascade,
rying to get at what might be optimal therapies for better
atient outcomes while balancing the risk of bleeding. Two
mall pilot trials were presented that provided preliminary
nformation on coagulation inhibition of tissue factor and
ctivated factor X (4,5). Both investigations, while prelim-
nary, suggested that more potent and more proximal
nhibition of coagulation is a promising strategy for ACS
are and deserves more research.
Mahaffey and Ferguson (6) presented preliminary data
rom the recently completed 10,000-patient Superior Yield
f the New strategy of Enoxaparin, Revascularization, and
lYcoprotein IIb/IIIa inhibitors (SYNERGY) trial, as part
f the Late-Breaking Clinical Trials section. This trial
nrolled high-risk ACS patients and tested enoxaparin, a
ow-molecular-weight heparin, against unfractionated hep-
rin. This was done on the backdrop of an early invasive
anagement strategy and other therapies, including other
ntithrombotics, as recommended by the ACC/American
eart Association (AHA) guidelines. The primary end
oint of the trial was the 30-day occurrence of death or MI.
he overall trial results showed no benefit of enoxaparin
ver unfractionated heparin; however, the investigators
eported that the trial did meet a prespecified secondary
bjective demonstrating non-inferiority.
Several important messages emerged from the SYN-
RGY trial. The first is that despite very aggressive therapy,
ncluding a high use of cardiac catheterization and revascu-
arization, these patients had 30-day event rates (composite
f death or MI) approaching 14%. These are very sick
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econd, we need to understand these therapies in the
ontext of broader real-life clinical trials, where we can
ssess whether or not a therapy offers advantages, particu-
arly to older patients and patients with multiple co-
orbidities, as we begin to combine multiple medicines.
Cannon et al. (7), from the Brigham and Women’s
ospital and the Thrombolysis In Myocardial Infarction
TIMI) study group, presented a very important trial that
as published simultaneously on-line in the New England
ournal of Medicine—the Pravastatin or Atorvastatin Eval-
ation and Infection Therapy (PROVE-IT) trial. This trial
ompared intensive and moderate lipid-lowering using
roven doses of pravastatin and untested, very high doses of
torvastatin among patients who had a recent ACS. This
as a randomized trial of over 4,000 patients, with approx-
mately 2,000 in each treatment group. The trial, interest-
ngly, was designed to demonstrate the non-inferiority of
ravastatin compared with the higher dose of atorvastatin.
he trial showed exactly the opposite: more intensive
ipid-lowering was associated with improved clinical out-
omes for this group of patients. This was a very important
bservation and a very practical one for clinicians taking care
f such patients.
schemic heart disease in women. One of the key themes
f this ACC meeting has been to better understand the
ender issues related to treatment modalities, as well as to
trategies of care. Information was presented by Blomkalns
t al. (8) from the University of Cincinnati using data from
he large Can Rapid risk stratification of Unstable angina
atients Suppress ADverse outcomes with Early implemen-
ation of the ACC/AHA guidelines (CRUSADE) registry,
hich involves over 400 U.S. hospitals dedicated to the
valuation of guideline-based care among patients with
on–ST-segment elevation ACS. She observed and re-
orted that there was more use in men versus women of a
umber of guideline-recommended acute therapies, includ-
ng aspirin, antithrombin therapy, intravenous antiplatelet
herapy, beta-blockade, and clopidogrel. With the exception
f beta-blockade, there was more use of each therapy in
en, even after adjusting for other severity markers of
llness, suggesting that we are offering differential treatment
o female compared with male patients.
This is important information, and it is not just with
egard to evidence-based medications, but other evidence-
ased strategies as well. Women were less likely than men to
et an electrocardiogram within 10 min of arrival. They
ere less likely to undergo early diagnostic catheterization
nd revascularization procedures. This work reported data
rom an observational registry, with all its inherent limita-
ions, but it warrants further research to understand these
ossible gender disparities in care.
iabetes. Diabetes has emerged as a national epidemic and
as particular relevance for those taking care of patients with
oronary atherosclerosis. Potentially important information
as presented by Miller et al. (9) from the Mayo Clinic on eehalf of the Collaborative Organization of Rheo-thRx
valuation (CORE) trial investigators. This trial evaluated
nfarct size, as measured by technetium sestamibi, and
xamined the outcomes stratified by the presence or absence
f diabetes. The group with diabetes had larger infarcts, as
easured by left ventricular ejection fraction and when
easured as a percentage of left ventricular involvement.
oth diabetes and infarct size also emerged as important
redictors of six-month mortality.
McGuire et al. (10), from Dallas, used the National
egistry of Myocardial Infarction database, totaling almost
.5 million patients, to examine the evolution of care of the
iabetic population from the early 1990s to 2002. They
bserved that the outcome of patients with diabetes mimics
he overall improvement in acute MI outcome; that is,
lthough overall acute MI care is improving, we can also see
n improvement in mortality in diabetic patients, particu-
arly among women with diabetes. So, there is some
otentially promising work being done here regarding both
ender and high-risk features of MI.
nflammation. Inflammation has received much attention
s a marker or predictor of risk among patients with ACS,
ncluding acute MI. We are now beginning to think about
argeting inflammation as a treatment strategy. Work pre-
ented by Theroux et al. (11), from the Montreal Heart
nstitute, on behalf of the COMplement Inhibition in
yocardial infarction treated with Angioplasty (COMMA)
nvestigators, concerned the complement inhibitor, pexeli-
umab; they noted that whether looking at C-reactive
rotein or interleukin-6, pexelizumab had the effect of
educing measures of inflammation. Pexelizumab is now
eing studied in a large-scale primary angioplasty trial, one
f the first major tests of the inflammation hypothesis in
cute MI care.
ypass surgery. Few issues in contemporary surgical revas-
ularization have gotten more attention and generated more
ontroversy than off-pump surgery. An important paper
resented at these meetings was a systematic overview of 41
tudies evaluating off-pump surgery (12). Although early
tudies demonstrated almost a 30% increased risk of early
eath with off-pump surgery compared with conventional
urgery, later studies indicated a survival advantage to
ff-pump surgery. The current analysis attributed the better
utcomes in the later studies to the greater use of cardiac
tabilization devices. This is a topic that continues to evolve,
nd more information is needed as clinicians consider which
ype of surgical revascularization to recommend for patients.
ellular therapy. Cell-based treatment strategies are on
he cusp of moving into the clinical research realm. Right
ow, much data are emerging from very early phase studies
bout the variety of ways to deliver cell-based therapies to
atients with ischemic heart disease. One of the areas
urrently undergoing most investigation is how to deliver
ell-based therapy to areas of infarction during bypass
urgery. In a preliminary project, 22 patients undergoing
lective bypass surgery had skeletal muscle—expanded
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ACC 2004 Annual Session Highlights July 21, 2004:10A–12Ayoblast populations—injected into an infarct zone at the
ime of surgery (13). The positron emission tomographic
cans and technetium scans showed that there was recovery
f myocardial viability in the infarct zone after cell
mplantation.
vidence-based medicine. Eagle et al. (14), from the
niversity of Michigan, provided updated information from
he Guidelines Applied in Practice (GAP) program as part
f a Late-Breaking Clinical Trials session. This program
valuates adherence to evidence-based therapies in acute MI
n Michigan. It involves a large cohort of Medicare patients
nd is measuring both short- and long-term mortality. The
urrent project was able to demonstrate that adherence to
he GAP program provided a better mortality gain than not
dhering to the GAP program. This is an important
essage that continues to emerge: hospitals and practitio-
ers who prescribe according to evidence-based techniques
ave better outcomes for their patients.
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